Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients

Autor: Silvia Frascerra, Andrea Tura, Andrea Mari, Stefania Camastra, Amalia Gastaldelli, Demetrio Ciociaro, Brenno Astiarraga, Ele Ferrannini
Rok vydání: 2016
Předmět:
0301 basic medicine
Blood Glucose
Male
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
Adipose tissue
0302 clinical medicine
Endocrinology
Glucagon-Like Peptide 1
Insulin-Secreting Cells
Insulin Secretion
Insulin
GLP-1 receptor agonist
endogenous glucose production
exenatide
glucagon
glucose metabolism
insulin resistance
insulin secretion
lipolysis
Fasting
Middle Aged
Postprandial Period
Glucagon-like peptide-1
Obesity
Morbid
Postprandial
Adipose Tissue
Liver
Female
medicine.drug
Adult
medicine.medical_specialty
Lipolysis
030209 endocrinology & metabolism
Gastric Inhibitory Polypeptide
Glucagon
03 medical and health sciences
Insulin resistance
Internal medicine
Internal Medicine
medicine
Humans
Hypoglycemic Agents
business.industry
Venoms
medicine.disease
030104 developmental biology
Exenatide
Insulin Resistance
business
Peptides
Zdroj: Diabetes, obesitymetabolism. 19(3)
ISSN: 1463-1326
Popis: Aims To investigate the effect of exenatide on glucose disposal, insulin secretion, s-cell function, lipolysis, and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions. Materials and methods Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months. Patients received a meal test/tracer study (MTT) to measure endogenous glucose production (EGP), rate of oral glucose appearance (RaO), insulin secretion rate (ISR), s-cell function, hepatic (HIR) and adipose tissue insulin resistance (AT-IR) and insulin sensitivity (IS). Results Post-treatment the EXE group showed a significant reduction in body weight (p
Databáze: OpenAIRE
Externí odkaz: